Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT06011343 Not yet recruiting - Clinical trials for Cutaneous Leishmaniasis, American

Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis

CLTofa23
Start date: October 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Phase 2/3 randomized and controlled clinical trial, which will evaluate the effectiveness of the association meglumine antimoniate (Glucantime) with tofacitinib in the cure of CL and the capacity of this association to reduce the time of cure of the disease.

NCT ID: NCT06010212 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

Start date: August 25, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This Study is a Single-center, Single-arm, Phase II Clinical Study. The Primary Objective is to Evaluate the Efficacy and Safety of Fruquintinib, Carrelizumab, Paclitaxel Liposomes combined with Nidaplatin as First-line Treatment in Advanced Esophageal squamous cell carcinoma .

NCT ID: NCT06010095 Not yet recruiting - Clinical trials for Recurrent Nasopharyngeal Carcinoma

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Start date: September 18, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving immunotherapy with nivolumab and ipilimumab and targeted therapy with cabozantinib may help shrink and stabilize nasopharyngeal cancer.

NCT ID: NCT06009393 Not yet recruiting - Clinical trials for Homozygous Familial Hypercholesterolemia

Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Start date: September 24, 2023
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label study to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with homozygous familial hypercholesterolemia (HoFH).

NCT ID: NCT06009107 Not yet recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)

B-ALL
Start date: August 31, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center, phase I/II trial to evaluate the safety and efficacy of HY004 treatment in Adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).

NCT ID: NCT06009029 Not yet recruiting - Clinical trials for Locally Advanced Pancreatic Cancer

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Start date: August 2023
Phase: Phase 2
Study type: Interventional

This trial is designed to investigate the efficacy and safety of patients with locally advanced pancreatic cancer by SBRT combined with Zimberelimab(GLS-010).

NCT ID: NCT06008730 Not yet recruiting - Clinical trials for Resectable Lung Non-Small Cell Carcinoma

Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer

Start date: August 1, 2024
Phase: Phase 2
Study type: Interventional

This clinical trial tests proton beam radiation therapy in patients with non-small cell lung cancer who have undergone surgical resection and have lymph nodes involving the middle of the chest. Proton therapy is a type of radiation treatment that kills cancer cells while avoiding surrounding healthy tissue. Proton beam therapy is sometimes used after cancer surgery to reduce the risk of cancer recurrence (coming back). Giving proton beam radiation therapy may work better than conventional radiation treatment after surgery in patients with non-small cell lung cancer.

NCT ID: NCT06008353 Not yet recruiting - Clinical trials for Extensive-stage Small-cell Lung Cancer

A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil

EDUR-BRA
Start date: November 17, 2023
Phase:
Study type: Observational

The central objective of this study is to characterize the demographic of an ES-SCLC Brazilian cohort treated with durvalumab. Secondarily, to assess the outcomes of durvalumab-based regimens in 1L treatment of ES-SCLC Brazilian patients from the private health care setting.

NCT ID: NCT06008275 Not yet recruiting - Breast Cancer Clinical Trials

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Start date: November 2023
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer. This trial will evaluate one dosing schedule of neratinib in ruxolitinib in patients with metTNBC with locoregional recurrence.

NCT ID: NCT06007833 Not yet recruiting - Exercise Clinical Trials

Physical Therapy Applications on the Hip and Defined Functional Parameters in Children With Developmental Hip Dysplasia

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The aim of this study was to investigate the effects of physical therapy and rehabilitation applications on the hip and defined functional parameters in children with developmental hip dysplasia.